# S-Biomedic NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/s-biomedic

- Industry: Healthcare
- Headquarters: Belgium
- Website: www.sbiomedic.com
- Total disclosed funding: $4.6M
- Latest round: Series A (Jan 3, 2019)
- Investors on record: 5

## About

Based in Belgium, S-Biomedic NV focuses on developing innovative skincare solutions that leverage the skin microbiome to improve skin health through targeted products, notably Sencyr®.S-Biomedic NV specializes in skincare innovations that target the skin microbiome. The company, headquartered in Belgium, was co-founded by Bernhard Paetzold and is currently led by CEO Veronika Oudova. In December 2022, Beiersdorf AG acquired a majority stake in S-Biomedic from various investors including Investiere.ch and DSM Venturing. The company has successfully raised EUR 2.00 mn through its latest funding round, Series A, with total funds raised also amounting to EUR 2.00 mn.S-Biomedic specializes in innovative skincare solutions focused on the modulation of the skin microbiome, primarily through its flagship product, Sencyr®. This product utilizes Living Skin Probiotics derived from the Cutibacterium microbe, which plays a key role in maintaining skin health. S-Biomedic aims to restore balance to the skin microbiome and addresses conditions such as acne, eczema, and rosacea. Products are distributed internationally, targeting markets with high demand for advanced skincare solutions.S-Biomedic generates revenue through direct-to-consumer sales and partnerships with established skincare brands, including Beiersdorf, which has collaborated with the company since 2018. The revenue model includes the sale of the proprietary Sencyr® product line, marketed through various skincare distributors and retailers, focusing on the premium skincare segment. For the most recent fiscal year 2023, S-Biomedic reported an EBITDA of EUR 2,130,152.90.S-Biomedic is actively working on expanding its product offerings, with upcoming launches expected to enhance its skincare line. The company is also looking to penetrate new geographical regions, particularly targeting markets in Europe by the end of 2024. Recent funding from the Series A round will support these initiatives, including further research and development to advance their product technologies. The acquisition by Beiersdorf AG is anticipated to facilitate this growth by leveraging their established market presence.

## Funding rounds

- Series A, Jan 3, 2019, $2.3M — DSM Venturing, Verve Ventures
- Series A, Jul 12, 2018, $2.4M — Johnson & Johnson Innovation, Beiersdorf AG, Verve Ventures
- Seed, Sep 6, 2016 — CG Health Ventures

## Investors

- CG Health Ventures (https://capitalatlas.ai/funds/cg-health-ventures) — Seed
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Beiersdorf AG — Series A
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series A
- DSM Venturing (https://capitalatlas.ai/funds/dsm-venturing) — Series A